Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Senti Biosciences (SNTI) presented promising preclinical data on its SENTI-202 CAR-NK cell therapy at the AACR Annual Meeting. This therapy targets CD33 and/or FLT3 for treating hematologic malignancies, showing enhanced cytotoxic activity and safety in in vitro and in vivo models. The company aims to submit an IND application by the second half of 2023, focusing on relapsed/refractory patients. Data on SENTI-301A further demonstrated CAR-NK cells' ability to improve persistence and anti-tumor efficacy. Overall, Senti Bio aims to revolutionize treatment for both liquid and solid tumors through its innovative gene circuit technology.
Senti Biosciences, Inc. (Nasdaq: SNTI), a biotechnology innovator in cell and gene therapies, announced its participation in several upcoming investor conferences. The events include:
- Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Date: April 24, 2023, 10:00 a.m. ET (Virtual) - Bank of America 2023 Global Healthcare Conference
Date: May 10, 2023 (Las Vegas, NV) - The JMP Securities Life Sciences Conference
Date: May 15, 2023, 2:30 p.m. ET (New York, NY)
Live webcasts will be available via the Senti Bio website, with archived replays accessible for 90 days after each event. Senti Bio aims to pioneer smarter therapies through its synthetic biology platform and proprietary Gene Circuit technology to enhance treatment precision in complex diseases.
Senti Biosciences (SNTI) reported significant advancements in its therapeutic pipeline, particularly with the upcoming IND application for SENTI-202 aimed at treating hematologic malignancies including AML and MDS, scheduled for submission in H2 2023. The company holds $98.6 million in cash and equivalents as of December 31, 2022, ensuring operational funding through at least Q1 2024. Research and development expenses increased to $34.1 million in 2022, compounded by substantial general and administrative costs of $40.8 million. The company recorded a net loss of $58.2 million for the year. Overall, Senti is positioned for ongoing growth with its innovative Gene Circuit technology.
Senti Biosciences (Nasdaq: SNTI) announces acceptance of three abstracts for presentation at the AACR Annual Meeting, scheduled for April 14-19, 2023, in Orlando, Florida. The abstracts focus on Senti Bio's proprietary CAR-NK cell therapies targeting hematologic malignancies and solid tumors. Notably, SENTI-202 is a logic gated CAR-NK cell therapy aimed at treating CD33/FLT3+ malignancies, with an IND submission planned for the second half of 2023. Additionally, data will showcase the enhanced capabilities of CAR-NK therapies through the incorporation of calibrated release IL-15. The presentations underline Senti Bio's innovative approaches and strategic partnerships to address oncology challenges.
Senti Biosciences, Inc. (Nasdaq: SNTI) announced the grant of stock options to 13 new employees, totaling 309,000 shares at an exercise price of $1.81, effective February 1, 2023. This action aligns with NASDAQ Listing Rule 5635(c)(4) and the 2022 Inducement Equity Plan. Senti Bio aims to innovate cell and gene therapies using its proprietary Gene Circuit technology, targeting complex diseases. Its lead candidate, SENTI-202, focuses on hematologic malignancies, while SENTI-401 addresses colorectal cancer and other CEA-positive cancers. The company has partnerships with Spark Therapeutics and BlueRock Therapeutics to enhance its capabilities.
Senti Biosciences, Inc. (Nasdaq: SNTI) announced its Co-Founder and CEO, Tim Lu, MD, PhD, will present at the virtual SVB Securities Global Biopharma Conference from February 13-16, 2023. Lu’s presentation is scheduled for February 16 at 3:40 PM ET. A live webcast can be accessed at this link and will be available for 90 days post-event. Senti Bio is advancing its Gene Circuit technology platform, targeting challenging cancers with its lead candidate, SENTI-202, and other programs like SENTI-401. For more details, visit Senti Bio's website.
Senti Biosciences (Nasdaq: SNTI) has announced a strategic focus on its lead oncology candidates, SENTI-202 and SENTI-401, for treating acute myeloid leukemia (AML) and colorectal cancer, respectively. The company is on track for an IND filing of SENTI-202 in the second half of 2023 and has extended its cash runway through at least Q1 2024. While the development of SENTI-301A for hepatocellular carcinoma (HCC) is deprioritized, Senti Bio aims to establish partnerships for its clinical progression. The advancements in gene circuit technology are expected to enhance therapy precision and effectiveness.
Senti Biosciences (Nasdaq: SNTI) will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 5:15 p.m. PT. Tim Lu, MD, PhD, Co-founder and CEO, will lead the presentation. The event can be viewed via webcast on the company’s website. Senti Bio is focused on developing next-generation cell and gene therapies using its innovative gene circuit platform. Their lead candidate, SENTI-202, targets hematologic malignancies, while SENTI-301A addresses hepatocellular carcinoma and other cancers.
Senti Biosciences announced at the ASH Annual Meeting progress on SENTI-202, an off-the-shelf CAR-NK cell therapy, showcasing preclinical data indicating effective targeting of CD33 and FLT3 expressing tumors, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The candidate is on track for an IND filing in 2H 2023. The data demonstrates significant cancer-killing activity in vitro and in vivo, while protecting healthy cells. This development highlights the potential for SENTI-202 to revolutionize treatment for patients with these hematologic malignancies.
Senti Biosciences, Inc. (Nasdaq: SNTI) will host an Investor Event on December 11, 2022, from 11:30 a.m. to 12:30 p.m. CST during the 64th ASH Annual Meeting in New Orleans, LA. The event will cover preclinical data and clinical plans for SENTI-202 aimed at treating hematologic malignancies like AML. Notable speaker Stephen A. Strickland, Jr., MD, will discuss the treatment landscape. Attendance is available in-person and virtually, with a webcast accessible on Senti's Events page.
The meeting is independent from the official ASH program.
FAQ
What is the current stock price of Senti Bioscience (SNTI)?
What is the market cap of Senti Bioscience (SNTI)?
